Llwytho...
Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
Despite being the least abundant immunoglobulin G in human plasma, IgG4 are used therapeutically when weak effector functions are needed. The increase in engineered IgG4-based antibodies on the market led us to study the patent landscape of IgG4 Fc engineering, i.e., patents claiming modifications i...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | MAbs |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6816381/ https://ncbi.nlm.nih.gov/pubmed/31556789 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1664365 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|